Stem is trading at $3.17, up 5.32% after its board announced a formal review of strategic alternatives.
- Stem hired financial and legal advisers; it set no timetable and cautioned that no transaction is assured.
- The October 23 NYSE non-compliance notice remains relevant background; the strategic review is the session’s primary company-specific catalyst.
- Third-quarter results are scheduled for November 5; a report also described Stem shares as higher following the announcement.